Step right up, ladies and gentlemen, and welcome to the hottest new spot in town: The Weight-Loss Casino! Here, you don’t ...

A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are ...

As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...

Roche is paying $1.65 billion in confirmed upfront fees to add to its burgeoning obesity pipelin | Roche is paying $1.65 ...

Compounded versions of popular drugs used for weight loss including Wegovy and Zepbound will soon no longer be available ...

Novo Nordisk’s weight loss drug Wegovy is linked to an increased risk of hair loss, a study suggests. Meanwhile, Dexcom ...

The multinational claims Mylan Pharmaceuticals’ generic of its blockbuster weight loss drug infringes another new patent | Complaint similar but separate to previous lawsuit against Mylan and Sun ...

Blockbuster GLP-1 medications are changing patient care, impacting surgery volumes and reshaping the financial landscape of the healthcare industry.

New trial data showed the drug helped obese or overweight type 2 diabetics lose an average 15.7% of their weight, when an ...

A sell-off across US markets has continued as investor sentiment soured amid growing fears that the world’s largest economy ...

Novo Nordisk A/S (NYSE: NVO) has declared that its GLP-1 drugs for chronic obesity, under the brands Ozempic and Wegovy, are ...